

NEWS RELEASE



Announcement Concerning Signing of Commitment Line Agreement

Tokyo, Japan, June 29th, 2018 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that Solasia has entered into a commitment line agreement (hereinafter “this agreement”) with Mizuho Bank, Ltd. Details are shown as follows.

1. Purpose of this agreement

As announced on June 13th 2018, due to the capital requirement for commercialization of SP-01 and SP-03, pivotal Phase II trial for SP-02 and initiation of global Phase III clinical study for SP-04, Solasia has concluded a commitment line agreement with the Sumitomo Mitsui Banking Corp. In addition, Solasia concluded this agreement with Mizuho Bank, Ltd. with loan limit of 1,500 million yen for the same purpose.

Following this agreement, the contracted bank loans are summarized as follows.

| | Overdraft facilities ; Loan limit | Commitment line agreement ; Loan limit |
|-------------------------------|--------------------------------------|---|
| Mizuho Bank, Ltd. | JPY 1,600 million | JPY 1,500 million |
| Sumitomo Mitsui Banking Corp. | JPY 1,000 million | JPY 1,000 million |

Note: As of today, there is no borrowing balance including the above loans.

2. Summary of the terms of this agreement

| | |
|---------------------|-------------------|
| Contracting party : | Mizuho Bank, Ltd. |
| Loan limit : | JPY 1,500 million |
| Contract date : | 29 June 2018 |
| Maturity date : | 28 June 2019 |
| Collateral : | None |

3. Impact on financial forecast

The impact of executing this agreement is immaterial to the current fiscal year’s financial forecast.

NEWS RELEASE

The Solasia logo features the word "Solasia" in a red, elegant serif font. The letter 'S' is notably larger and more stylized than the other letters.

About Solasia:

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

Additional information is available at <http://www.solasia.co.jp/en/>

(Contact)

Solasia Pharma K.K.

Rie Toyoda

Investor Relations

+81-3-5843-8049

info@solasia.co.jp